IFNB1 and myeloid sarcoma: The estimated incidence of IFNβ-related TMA in patients with MS was reported to be 7.2 per 100,000 patient-years [25], but this figure is expected to increase as the number of MS patients treated with IFNβ for more than 6 to 10 years has been growing.